Dare Bioscience, Inc. Stock News

Daré Bioscience, Inc. (NASDAQ:DARE ) Q4 2024 Earnings Conference Call March 31, 2025 4:30 PM ET Company Participants MarDee Haring-Layton - Chief Accounting Officer Sabrina Martucci Johnson - President & Chief Executive Officer Conference Call Participants Catherine Novack - Jones Trading Douglas Tsao - H.C. Wainwright Kemp Dolliver - Brookline Capital Markets Operator Welcome to the conference...

With increasing demand for needed treatments designed for women, Daré is taking action to make its proprietary Sildenafil Cream formulation available via prescription this year With increasing demand for needed treatments designed for women, Daré is taking action to make its proprietary Sildenafil Cream formulation available via prescription this year

SAN DIEGO, March 24, 2025 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and well-being of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Monday, March 31, 2025, to review its financial results for the year ended December 31, 2024, and to provide a company update.

DARE-HPV is a potential first-in-category treatment for human papillomavirus (HPV)-related cervical disease which could change the treatment paradigm for clinical HPV management

The panel will discuss the value proposition for investing in women's health. J.P. Morgan is hosting a three-panel women's health series at this year's conference to highlight the importance of innovation and growing visibility around women's health.

Daré Bioscience, Inc. (NASDAQ:DARE ) Q3 2024 Earnings Conference Call November 14, 2024 4:30 PM ET Company Participants MarDee Haring-Layton - CAO Sabrina Martucci Johnson - President and CEO Conference Call Participants Catherine Novack - JonesTrading Brian Kemp Dolliver - Brookline Capital Markets Douglas Tsao - H.C. Wainwright Operator Welcome to the conference call hosted by Daré Bioscience...

Conference Call and Webcast Today at 4:30 p.m. ET Development Program Highlights and Anticipated Milestones Ovaprene® hormone-free monthly intravaginal contraceptive candidate – pivotal Phase 3 contraceptive efficacy study recruiting across the United States; foundation grant announced yesterday will provide funding to allow Daré to expand the number of clinical sites to accelerate the developm...

SAN DIEGO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in innovation for the health and wellbeing of women, will host a conference call and live webcast at 4:30 p.m. Eastern Time on Thursday, November 14, 2024, to review its financial results for the quarter ended September 30, 2024 and to provide a company update. The company will release its financial res...